Australia, March 24 -- REGENXBIO Inc., owns the trademark (2613378) for 'NAVGENVYS' till Nov. 5, 2035.
Status: protected:
Registered/protected
Class: 5 [Biological preparations for medical use in the treatment of genetic diseases and disorders, and muscle disorders, namely, Duchenne muscular dystrophy; pharmaceutical preparations, namely, recombinant adeno-associated viral (rAAV) vectors for use in gene therapy; pharmaceutical preparations for the treatment of genetic diseases and disorders, and muscle disorders, namely, Duchenne muscular dystrophy; clinical medical reagents for use in gene therapy; therapeutic pharmaceutical compositions that include recombinant adeno-associated viral (rAAV) vectors to provide a platform for specific expression of biologics with therapeutic effect in gene therapy; pharmaceutical preparations containing adeno-associated viral (AAV) vectors and nucleic acids for a system delivering genes to biological cells for use in the treatment of genetic diseases and disorders, namely, Duchenne muscular dystrophy; gene therapy preparation for medical use containing genetic materials for sustained protein expression, namely, microdystrophin expression.]
Type of Mark: Word
Date of Acceptance: Jan. 16
Registration Advertised: March 23
For further details contact William R. Samuels Cole-Frieman & Mallon LLP .
The original document can be viewed at: https://search.ipaustralia.gov.au/trademarks/search/view/2613378.
Disclaimer: Curated by HT Syndication.
